Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Jul 25, 2025
Dividend Increases/Decreases for the Week of July 25
Let's take a look at firms raising/lowering their dividends this week. Jul 24, 2025
Chipotle Now Expects Flat Comps for 2025
Image Source: Valuentum. Looking to 2025, Chipotle now expects flat full year comparable restaurant sales (was low to mid-single digits) and plans to open 315-345 new company-owned restaurants with over 80% having a Chipotlane. We like Chipotle’s long-term restaurant growth potential and believe its negative comps registered in the second quarter are temporary. Shares remain an idea in the Best Ideas Newsletter portfolio. Jul 24, 2025
Alphabet Puts Up Excellent Second Quarter Results
Image Source: TradingView. In Alphabet’s second quarter, total operating income increased 14%, as its operating margin came in at 32.4% benefiting from strength in the top line and “continued efficiencies in the expense base." Net income increased to $28.2 billion, up from $23.6 billion in the same quarter of 2024, while diluted earnings per share increased to $2.31 from $1.89 in the year-ago period. Alphabet ended the quarter with $95.1 billion in total cash and marketable securities and long-term debt of $23.6 billion. Through the first six months of the year, free cash flow was $24.3 billion. We like Alphabet as one of the top ideas in the Best Ideas Newsletter portfolio. Jul 23, 2025
NextEra Energy’s Outlook for the Next Few Years Looks Solid
Image Source: NextEra Energy. NextEra’s long-term outlook remains unchanged. For 2025, NextEra Energy expects adjusted earnings per share to be in the range of $3.45-$3.70. For 2026 and 2027, NextEra expects adjusted earnings per share to be in the ranges of $3.63-$4.00 and $3.85-$4.32, respectively. The company also expects to increase its dividends per share at a roughly 10% rate per year through at least 2026, off a 2024 base. We continue to like NextEra Energy as our utility exposure and think it makes sense as a key position in the ESG Newsletter portfolio. Jul 23, 2025
Philip Morris’ Smoke-Free Portfolio Continues to Gain Traction
Image Source: TradingView. Looking to 2025, Philip Morris is targeting reported diluted earnings per share in the range of $7.24-$7.37 versus $4.52 last year. Adjusted diluted earnings per share is expected in the range of $7.43-$7.56 versus $6.57 last year. Adjusted diluted earnings per share, excluding currency, is budgeted in the range of $7.33-$7.46 versus $6.57 last year. In the second quarter, Philip Morris’ smoke-free business accounted for 41% of total net revenue, as it continues to benefit in part from rampant ZYN adoption. In the U.S., “ZYN reaccelerated its offtake growth to approximately 36% in June, and 26% in Q2 overall as measured by Nielsen." We continue to like Philip Morris’ smoke-free business and have no qualms with it as a idea in the High Yield Dividend Newsletter portfolio. Jul 23, 2025
Lockheed Martin Announces Program Losses
Image Source: TradingView. Looking to 2025, Lockheed Martin reiterated its sales guidance in the range of $73.75-$74.75 billion, but it cut its business segment operating profit expectations for the year to the range of $6.6-$6.7 billion from $8.1-$8.2 billion. Diluted earnings per share for 2025 is now expected in the range of $21.70-$22.00, down from the range of $27.00-$27.30 previously. Lockheed maintained its cash flow from operations guidance for 2025 in the range of $8.5-$8.7 billion. It also maintained its free cash flow guidance for the year in the range of $6.6-$6.8 billion. We didn’t like the announced pre-tax losses on programs but were encouraged that Lockheed stuck with its annual free cash flow outlook. Lockheed Martin remains an idea in the Dividend Growth Newsletter portfolio. Jul 23, 2025
Domino’s Same Store Sales Growth Beats Expectations
Image Source: Domino's. During the quarter, Domino’s global net store growth was 178, consisting of 30 net store openings in the U.S. and 148 net store openings internationally. Net income in the quarter declined 7.7%, but this was primarily due to an unfavorable charge of $27.4 million associated with the company’s investment in DPC Dash Ltd and a higher effective tax rate. Diluted earnings per share was $3.81 in the second quarter, down from $4.03 in the second quarter of 2024. Net cash provided by operating activities was $366.9 million in the first half of 2025, up from $274.2 million, and free cash flow was $331.7 million in the first half of 2025, compared to $230.5 million in the first half of 2024. We continue to like Domino’s as an idea in the Best Ideas Newsletter portfolio. Jul 20, 2025
Kinder Morgan Expected to Capitalize on Natural Gas Demand
Image Source: TradingView. Looking to 2025, Kinder Morgan expects net income to be $2.8 billion, up 8% when compared to last year’s tally. Adjusted earnings per share is targeted at $1.27, which is 10% better than the mark achieved in 2024. Kinder Morgan expects to declare dividends of $1.17 per share for 2025, which represents an increase of 2% from dividends declared in 2024. Finally, the pipeline giant has budgeted 2025 adjusted EBITDA of $8.3 billion, up 4% versus 2024, while it plans to end 2025 with a net debt-to-adjusted EBITDA ratio of 3.8 times. We like Kinder Morgan, but don’t include shares in any newsletter portfolio. Jul 20, 2025
Johnson & Johnson Raises 2025 Guidance
Image Source: J&J. Looking to all of 2025, J&J raised its adjusted operational sales growth target to the range of 3.2%-3.7%, up from 2%-3% previously. Adjusted operational earnings per share for the year is expected in the range of $10.63-$10.73, up from $10.50-$10.70 previously, implying growth of 6.5%-7.5% versus the prior year. In the press release, management noted “significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA.” We like J&J, but don’t include shares in any newsletter portfolio.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353354355356357358359360 361362363364365366367368369370371372373374375376377378379380 381382383384385386387388389390391392393394395396397398399400 401402403404405406407408409410411412413414415416417418419420 421422423424425426427428429430431432433434435436437438439440 441442443444445446447448449450451452453454455456457458459460 461462463464465466467468469470471472473474475476477478479480 481482483484485486487488489490491492493494495496497498499500 501502503504505506507508509510511512513514515516517518519520 521522523524525526527528529530531532533534535536537538539540 541542543544545546547548549550551552553554555556557next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
Image Source: TradingView. Year-to-date, IBM’s net cash from operating activities was $6.1 billion, with free cash flow coming in at $4.8 billion. IBM ended the second quarter with $15.5 billion of cash and marketable securities against debt, including IBM Financing debt of $11.7 billion, of $64.2 billion, up $9.2 billion year to date. Looking to full year 2025 expectations, IBM continues to expect constant currency revenue growth of at least 5%, and the firm now expects to generate more than $13.5 billion in free cash flow for the full year. We like IBM’s focus on free cash flow, but we don’t include shares in any newsletter portfolio.